The IMP, tTF-NGR (His-tag-tTF1-218-GNGRAHA), is the lead compound of our series of fusion proteins carrying tumor-targeting peptides instead of the transmembrane domain at the C-terminus of truncated tissue factor for induction of tumor infarction [13,14,15,16,17,18,19,20]. This evidence concerns the gene RTN4R and neoplasm.